Core Viewpoint - GRAIL, Inc. is set to release its financial results for the fourth quarter of 2024 on February 20, 2025, followed by a conference call to discuss the results and business progress [1]. Company Overview - GRAIL is a healthcare company focused on early cancer detection, utilizing next-generation sequencing, clinical studies, and advanced machine learning to identify multiple cancer types at earlier stages [4]. - The company aims to alleviate the global burden of cancer through its targeted methylation-based platform, which supports various aspects of cancer care, including early detection, risk stratification, and treatment monitoring [4]. - GRAIL is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom [4]. Event Details - A live webcast and recorded replay of the financial results announcement will be available on GRAIL's investor relations website [2]. - Participants are encouraged to register for the teleconference and join the webcast at least ten minutes prior to the scheduled start time [3].

Core Viewpoint - GRAIL, Inc. and Quest Diagnostics have launched a program to enhance access to GRAIL's Galleri multi-cancer early detection test for healthcare providers in the U.S., streamlining the ordering process and improving patient access to the test [1][2][3] Group 1: Collaboration and Integration - The integration of the Galleri test into Quest's connectivity system allows providers to order the test electronically, enhancing efficiency in the ordering process [1][3] - Quest Diagnostics has approximately 7,400 patient access points nationwide, enabling patients to access the Galleri test without needing to bring a test kit to their appointment [2][3] Group 2: Cancer Detection Capabilities - The Galleri test detects DNA fragments shed by cancers, acting as a "fingerprint" to identify multiple deadly cancers before symptoms appear, including those without recommended screening tests [3][4][7] - The test is recommended for adults aged 50 or older and is intended to be used alongside standard cancer screenings [4][10] Group 3: Sensitivity and Effectiveness - The Galleri test shows high sensitivity for various cancers, including pancreas cancer (83.7% overall), esophagus cancer (85.0% overall), ovary cancer (83.1% overall), and liver/bile duct cancer (93.5% overall) [9]

Grail Stock Performance and Technical Analysis - Grail (GRAL) shares surged to a new record high, gaining 64% last week amid optimism about the company's early-detection cancer screening blood tests [2][4] - The stock's rally was fueled by comments from Oracle's Larry Ellison, who highlighted the potential of combining early detection blood tests with AI and gene sequencing to develop personalized cancer vaccines [3] - Grail shares broke out above the neckline of a cup and handle pattern on Thursday, with gains continuing through Friday's session, supported by the highest trading volume since mid-December [5] Technical Indicators and Price Targets - The relative strength index (RSI) confirms bullish price momentum, though it registered an overbought reading on Friday, suggesting potential for near-term profit-taking [6] - Using the measured move technique, an upside target of $46 is projected by applying a 100% increase to the cup and handle's neckline value of $23 [7][8] - Key support levels to monitor during pullbacks include $23, near the cup and handle pattern's neckline, and $20, a psychological level near a trendline connecting historical peaks and troughs [9][10] Industry Context and Market Focus - Grail's early-detection cancer screening blood tests are gaining attention in the medical technology sector, with potential applications in AI and gene sequencing for personalized cancer vaccines [2][3] - The company, spun off from Illumina Health last June, remains in focus as its stock continues to attract investor interest following its recent breakout and strong performance [4][11]

Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection TestingMENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The PATHFINDER study included secondary and exploratory outcomes wi ...

MENLO PARK, Calif., Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15 at 9:00 a.m. PT.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 d ...

Grail TodayGRALGrail$22.16 +1.38 (+6.64%) 52-Week Range$12.33▼$23.44Price Target$16.00Add to WatchlistGRAIL NASDAQ: GRAL is a small-cap biotechnology company that has gone on a very strong run over the last month and a half. Shares of the healthcare stock are up 58% since Oct. 24, as of the Dec. 11 close. The company has interesting technology that sets it apart from many small biotechs. I'll explain what this firm does, its uniqueness, and my view on this stock that targets a $100 billion market. Get Grai ...

MENLO PARK, Calif., Dec. 3, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 115,093 shares of GRAIL's common stock to 46 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement E ...

MENLO PARK, Calif., Nov. 19, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will participate in the following investor conferences. Piper Sandler 36th Annual Healthcare Conference in New York, NY: fireside chat on Tuesday, Dec. 3 at 1:30 p.m. ET 7th Annual Evercore ISI HealthCONx Conference in Coral Gables, Fla.: fireside chat on Wednesday, Dec. 4 at 3:50 p.m. ETLive and replay webcas ...

MENLO PARK, Calif., Nov. 18, 2024  /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca (LSE/STO/Nasdaq:AZN) in collaborat ...

Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $28.7 million, an increase of $7.9 million or 38% compared to Q3 2023 [16] - Screening revenue was $25.4 million, up 52% from Q3 2023, driven by increased sales volume [18] - Net loss for the quarter was $125.7 million, an improvement of 86% compared to Q2 2023 [19] - Non-GAAP adjusted gross profit for Q3 2024 was $11.8 million, an increase of $4.8 million or 68% compared to Q3 2023 [21] - Adjusted EBITDA for Q3 2024 was a negative $108.2 million, representing an improvement of $17.9 million or 14% compared to Q3 2023 [21] - Cash position at the end of the quarter was $853.6 million [21] Business Line Data and Key Metrics Changes - Approximately 32,600 Galleri tests were sold in Q3 2024, reflecting continued demand [18] - Development services revenue was $3.3 million, which includes services provided to biopharmaceutical and clinical customers [17] Market Data and Key Metrics Changes - Over 250,000 commercial Galleri tests have been prescribed by more than 12,000 healthcare providers since launch [9] - A cancer signal detection rate of 1.3% was observed in a study of 2,800 veterans, with a positive predictive value of 42.9% [14] Company Strategy and Development Direction - The company aims to improve cancer care and enable broad use of Galleri, focusing on FDA approval and pursuing broad reimbursement [24] - A new version of the Galleri test is expected to launch at the end of the year, featuring significant automation and cost reductions [10][29] - The company plans to moderate cash burn and extend its cash runway into 2028 while prioritizing FDA approval and reimbursement [22][34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the demand for Galleri and the potential for future growth, despite the challenges of being an unreimbursed test [9][30] - The company is encouraged by bipartisan support for legislation that could facilitate CMS coverage for FDA-approved tests [30] Other Important Information - The company is narrowing its guidance for Galleri sales growth in 2024 to between 40% and 50% compared to 2023 [22] - The expected timeline for FDA approval is tentatively set for the first half of 2027 [28] Q&A Session Summary Question: Progress on Galleri reimbursement and FDA regulatory pathway - Management discussed the completion of study visits for key registrational studies and the expected timeline for PMA submission in the first half of 2026, with FDA approval anticipated in the first half of 2027 [27][28] Question: Managing commercial efforts and cash balance - The company is focusing on extending its cash runway while moderating investment in commercial efforts to ensure that margins generated can cover expenses [33][34] Question: Building the MCED market before reimbursement - Management emphasized the importance of integrating Galleri into standard practices and building provider comfort with the test [38] Question: Performance differences in version 2 of Galleri - Minor improvements in performance are expected, but the main focus is on scalability and cost reduction [42] Question: Phasing of cash burn through 2025 - Cash burn is expected to decrease as revenues grow, with a gradual ramp-up in cost reductions from the new version of Galleri [45][46]